Antitopoisomerase drug action and resistance
Authors:
- J.L. NitissJNJ.L. Nitiss
- W.T. BeckWBW.T. Beck
- 1 June 1996
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 32 (6) , 958-966
Abstract
No abstract availableThis publication has 64 references indexed in Scilit:
- DNA topoisomerase II mutations and resistance to anti‐tumor drugsBioEssays, 1995
- A Mutation in Yeast TOP2 Homologous to a Quinolone-resistant Mutation in BacteriaJournal of Biological Chemistry, 1995
- Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 1995
- A topoisomerase II-dependent G2 cycle checkpoint in mammalian cellsNature, 1994
- Discrete Localization of Different DNA Topoisomerases in HeLa and K562 Cell Nuclei and Subnuclear FractionsExperimental Cell Research, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase IJournal of Molecular Biology, 1992
- Mode of action of topoisomerase II-targeting agents at a specific DNA sequenceJournal of Molecular Biology, 1992
- Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase IIJournal of Molecular Biology, 1992
- A novel pathway of DNA end-to-end joiningCell, 1990